[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists]. 2006

Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine, Japan. muramatsu@fmsrsa.fukui-med.ac.jp

Alpha(1)-adrenoceptors are widely distributed in the human body and play important physiologic roles. Three alpha(1)-adrenoceptor subtypes (alpha(1A), alpha(1B) and alpha(1D)) have been cloned and show different pharmacologic profiles. In addition, a putative alpha(1)-adrenoceptor (alpha(1L) subtype) has also been proposed. Recently, three drugs (tamsulosin, naftopidil, and silodosin) have been developed in Japan for the treatment of urinary obstruction in patients with benign prostatic hyperplasia. In this review, we describe recent alpha(1)-adrenoceptor subclassifications and the pharmacologic characteristics (subtype selectivity and clinical relevance) of alpha(1)-adrenoceptor antagonists.

UI MeSH Term Description Entries
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077409 Tamsulosin A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA. 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide,Flomax,LY 253352,LY-253352,Tamsulosin Hydrochloride,YM 617,YM-617
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
June 1999, European journal of pharmacology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
February 2010, Cellular and molecular life sciences : CMLS,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
July 2005, The Journal of urology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
April 2008, Zhonghua nan ke xue = National journal of andrology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
June 2001, Japanese journal of pharmacology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
April 2000, Canadian journal of physiology and pharmacology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
January 1999, European urology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
January 1999, European urology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
June 1999, Naunyn-Schmiedeberg's archives of pharmacology,
Ikunobu Muramatsu, and Fumiko Suzuki, and Takashi Tanaka, and Hatsumi Yamamoto, and Shigeru Morishima
September 2006, Journal of molecular graphics & modelling,
Copied contents to your clipboard!